Anti-viral action against Type 1 diabetes autoimmunity

More than two thousand children with a genetic predisposition to type 1 diabetes will receive either a COVID-19 vaccine or a placebo starting at six months of age, to see if the shot can prevent the immune system from attacking the pancreas. Type 1 diabetes is an autoimmune disease in which the body mistakenly destroys the insulin-producing cells of the pancreas. Researchers suspect that viral infections—including COVID-19—may act as a trigger that sets off this autoimmune attack in genetically susceptible children. If that link is real, then vaccinating against the virus might block the trigger and prevent the disease from ever starting. If the trial shows that vaccination reduces the appearance of islet autoantibodies (the first biological sign of autoimmunity) or full-blown type 1 diabetes, it would offer a simple, safe preventive strategy for children at elevated genetic risk. Currently, there is no way to stop type 1 diabetes before it begins; families can only manage the condition after diagnosis. A successful result could shift the approach from lifelong treatment to early prevention, fundamentally changing how the disease is managed in childhood.